Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The rapid emergence of antimicrobial-resistant strains of Neisseria gonorrhoeae threatens treatment options and control efforts. The Uniformed Services University Gonococcal Reference Laboratory and Repository of the Global Emerging Infections Surveillance Program receives isolates from several geographically distinct regions worldwide. We analyzed 962 isolates collected during 2014-2022 for genomic and phenotypic antimicrobial resistance.
View Article and Find Full Text PDFAntimicrobial activity of compounds identified by artificial intelligence discovery engine targeting enzymes involved in Neisseria gonorrhoeae peptidoglycan metabolism.
Biol Res
September 2024
Neisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, England, SO16 6YD.
Background: Neisseria gonorrhoeae (Ng) causes the sexually transmitted disease gonorrhoea. There are no vaccines and infections are treated principally with antibiotics. However, gonococci rapidly develop resistance to every antibiotic class used and there is a need for developing new antimicrobial treatments.
View Article and Find Full Text PDFCyclization increases bactericidal activity of arginine-rich cationic cell-penetrating peptide for .
Microbiol Spectr
September 2024
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.
We previously reported that a linear cationic 12-amino acid cell-penetrating peptide (CPP) was bactericidal for . In this study, our objectives were to determine the effect of cyclization of the linear CPP on its antibacterial activity for and cytotoxicity for human cells. We compared the bactericidal effect of 4-hour treatment with the linear CPP to that of CPPs cyclized by a thioether or a disulfide bond on human challenge and multi-drug resistant (MDR) strains of grown in cell culture media with 10% fetal bovine serum (FBS).
View Article and Find Full Text PDFIn silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions.
J Antimicrob Chemother
September 2024
Institute for Global Health, Faculty of Population Health, University College London, London, UK.
Article Synopsis
- The study explores gepotidacin, a new treatment for gonorrhea, and investigates genetic changes in the GyrA and ParC targets of gonococci using a large dataset of genomes.
- Key findings show that alterations at GyrA position A92 are rare, while changes at ParC position D86 are more common, but neither type resulted in resistance to gepotidacin.
- The authors emphasize the importance of monitoring potential antimicrobial resistance and using effective MIC testing methods to ensure gepotidacin remains effective against gonorrhea.
A laboratory-based predictive pathway for the development of high-level resistance to corallopyronin A, an inhibitor of bacterial RNA polymerase.
Microbiol Spectr
June 2024
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
Unlabelled: The continued emergence of strains that express resistance to multiple antibiotics, including the last drug for empiric monotherapy (ceftriaxone), necessitates the development of new treatment options to cure gonorrheal infections. Toward this goal, we recently reported that corallopyronin A (CorA), which targets the switch region of the β' subunit (RpoC) of bacterial DNA-dependent RNA polymerase (RNAP), has potent anti-gonococcal activity against a panel of multidrug-resistant clinical strains. Moreover, in that study, CorA could eliminate gonococcal infection of primary human epithelial cells and gonococci in a biofilm state.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!